MOLOGEN AG has developed numerous unique technology platforms in-house that offer a remarkably wide range of possible applications. These technology platforms also form the basis for the first highly promising medicines that are currently in various stages of research and clinical development.

The wide scope of the dSLIM® and MIDGE® technology platforms and the allogeneic tumor cell bank is also reflected in the individual products' potential areas of use: MOLOGEN's product pipeline comprises DNA cancer therapies for multiple indications, DNA vaccine candidates for vaccinations against infectious diseases and cell-based gene therapy against cancer.

dSLIM® - With its dSLIM® DNA molecule, MOLOGEN has created a modern tool capable of exerting a specific influence on the patient's immune system (a process known as immunomodulation). Of note is the fact that this immunomodulator is extremely versatile and can be used for a variety of possible applications in the field of cancer treatments. It can also be used as an enhancer (or adjuvant) in combination with other treatment approaches or drugs.

MIDGE® - With our development of the MIDGE® vector system, we have created the basis for a broad spectrum of modern, DNA-based applications. The vectors can be equipped with various customized genetic information. This makes them ideal both for the genetic modification of tumor cells in the context of cell-based gene therapy against cancer as well as for DNA-based vaccinations against infectious diseases. The vectors can be used for prophylactic and therapeutic vaccinations.

Allogeneic tumor cell bank - The tumor cell line established by MOLOGEN offers a unique platform for cell-based therapy against cancer. The tumor cell line has been established as a cell bank in accordance with drug law specifications. The cells can be genetically modified using MIDGE® vectors, thereby adapting them to their intended purpose.